Somatostatin receptor imaging with 111In-pentetreotide in gastrointestinal tract and lung neuroendocrine tumors-Impact on targeted treatment

Hellenic Journal of Nuclear Medicine

Volumn 13, Issue 2, 2010, Pages 158-162

  Gerasimou, George ^a   Moralidis, Efstratios ^a   Gotzamani Psarrakou, Anna ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Gastro entero pancreatic tumors; Octreoscan; Small cell lung carcinoma; Somatostatin

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; LUTETIUM 177; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; GASTROINTESTINAL TUMOR; HUMAN; INSULINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NEUROENDOCRINE TUMOR; NEUROENDOCRINE TUMOR; IN 111; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MOLECULAR IMAGING; NEUROENDOCRINE TUMORS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 77956389141     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. th edn, Lippincott, Williams and Wilkins pub. Philadelphia 2000; Section II, Ch 403: 2663-81.
2. Reubi JC, Laissue J, Krenning EP et al. Somatostatin receptors in human cancer: incidence,characteristics, functional correlates and clinical implications. J Steroid Biochem 1992; 43: 27-35.
3. Reubi JC, Kvols L, Krenning EP et al. Distribution of somatostatin receptors in normal and tumour tissue. Metabolism 1990; 39 (suppl): 78-81.
4. Reubi JC, Kvols L, Krenning EP et al. In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncologica 1991; 30: 463-8.
5. Reubi JC, Chayvialle JA, Franc B et al. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64: 567-73.
6. 123I]SDZ 204-090). J Clin Endocrinol Metab 1991; 73: 851-6.
7. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogues in the diagnosis and treatment of tumors. Endocrine Rev 1991; 12: 450-82.
8. 111In-Pentetreotide); Product Monograph, Mallinckrodt Medical Inc 2006; 9-19.
9. Jensen RT, Gibril F, Termanini B. Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. Yale J Biol Med 1997; 70: 481-500. (Pubitemid 28515733)
10. Schrebul H, Bader M, Fett U et al. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 1993; 105: 1705-9.
11. Gotthardt M, Dirkmorfeld LM, Wied MU et al. Influence of somatostatin receptor scintigraphy and CT/MRI on the clinical management of patient with gastrointestinal neuroendocrine tumors: an analysis of 188 patients. Digestion 2003; 68: 80-5.
12. 111In-DTPA- pentetreotide scintigraphy in accurate diagnosis of neuroendocrine gastroenteropancreatic tumors.J Hepatobiliary Pancreat Surg 2001; 8: 473-8.
13. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and tumors. The WHO classification. Ann N Y Acad Sci 2004; 1014: 13-27.
14. Cuikla JB, Nasierowska-Guttmejer A, Jeziorski KG et al. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin-single NET center experience in Poland Neuro Endocrinol Lett. 2007; 28: 789-800.
15. Savelli G, Lucignani G, Seregni E et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero- pancreatic (GEP) neuroendocrine tumors. Nucl Med Commun 2004; 25: 445-9.
16. Gerasimou G, Aggelopoulou T, Papanastasiou E et al. Indium-111-DTPA phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography. Hell J Nucl Med 2007; 10: 209-14
17. Chiti A, van Graafeiland BJ, Savelli G et al. Imaging of neuroendocrine gastro-entero-pancreatic tumors using radiolabelled somatostatin analogues. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2: S190-4. (Pubitemid 29527893)
18. Chiti A, Fanti S, Savelli G et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumors. Eur J Nucl Med 1998; 25: 1396-1403.
19. Chiti A, Spinelli A, Bombardieri E. The scintigraphy of somatostatin receptors ingastroenteropancreatic neuroendocrine tumors. Radiol Med (Torino) 1997; 94: 362-70.
20. Schillaci O, Corleto VD, Annibale B et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero-pancreatic tumors. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2: S186-9.
21. Chiti A, Briganti V, Fanti S et al. Results and potential of somatostatin receptor imaging in gastro- entero-pancreatic tract tumors. Q J Nucl Med. 2000; 44: 42-9. (Pubitemid 30325952)
22. Briganti V, Matteini M, Ferri P et al. Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors. Cancer Biother Radiopharm 2001; 16: 515-24.
23. Krausz Y, Bar-Ziv J, de Yong RB et al. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastoenterol. 1998; 93: 66-70.
24. Bombardieri E, Macauro M, De Deckere E et al. Nuclear medicine imaging of neuroendocrine tumors. Ann Oncol. 2001;12, Suppl 2: S51-61.
25. Pasquali C, Sperti C, Lunardi C et al. Positron emission tomography with fluorodeoxyglucose in gastro-entero-pancreatic tumors: diagnostic role and prognostic implications. Suppl Tumori. 2005; 4: S68-71.
26. O'Byrne KJ, Halmos G, Pinski J et al. Somatostatin receptor expression in lung cancer. Eur J Cancer. 1994; 30A: 1682-7.
27. 111In-DTPA- octreotide: a preliminary study. Nucl Med Commun 1993; 14: 962-8.
28. Hoefer M, Schmidt S, Welter J et al. Diagnostic value of somatostatin receptor scintigraphy with indium-111 pentetreotide in small-cell bronchial carcinoma. Pneumologie. 1998; 52: 106-12.
29. Reisinger I, Bohuslavitzki KH, Brenner W et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med. 1998; 39: 224-7.
30. 111In- octreotide scintigraphy in small cell lung cancer. Q J Nucl Med. 1995; 39, Suppl 1: 108-10.
31. Tzannou IA, Karapanagiotou EM, Charpidou A et al. The use of radiolabeled somatostatin analogue scintigraphy in the staging of small cell lung patients. Am J Clin Oncol 2007; 30: 503-6. (Pubitemid 47537951)
32. 99mTc-MDP in bone metastases of small-cell lung cancer. Hell J Nucl Med 2009; 12: 283-4.
33. 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009; 50: 1214-21.
34. Lau SK, Johnson DS, Coel MN. Imaging of non-small-cell lung cancer with Indium-111 pentetreotide. Clin Nucl Med 2000; 25: 24-8.
35. 111In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32: 110-22.
36. 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med 2000; 44: 88-95.
37. Anthony LB, Woltering EA, Espenan GD et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32:123-32.
38. Cuccurullo V, Gascini GL, Rambaldi PF et al. Role of somatostatin analogs in the treatment of neuroendocrine tumours. Minerva Endocrinol 2001; 26: 135-43.
39. Kwekkeboom DJ, de Herder WW, van Eijck CH et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumours. Semin Nucl Med. 2010; 40: 78-88.
40. Kwekkeboom DJ, Kam BL, van Essen M et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010; 29: R53-73.
41. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ, and tumor uptake. J Nucl Med 1999; 40: 762-7.
42. Kong G, Johnston V, Ramdave S et al. High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. Cancer Biother Radiopharm. 2009; 24: 527-33.
43. 90Y-Dotatoc and selective internal radiation treatment (SIRT). Hell J Nucl Med 2009; 2: 266-70.
44. 68Ga-DOTATOC-PET/CT. Eur J Nucl Med Mol Imaging 2009; 36: 48-52.
45. 90Y-DOTATOC therapy for tumor down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Arch Surg 2009; 2: 185-92.
46. 90Y-Dotatoc. Hell J Nucl Med 2009; 2: 161-4.
47. 111In-DTPA-D-Phe1-octreotide and Yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nucl Med Commun 2008; 29: 283-90.
48. 86Y-DOTA-D-Phe1-Tyr3- octreotide (SMT487)-a phase1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino-acid co-infusion. Eur J Nucl Med Mol Imaging 2003; 30: 510-8.
49. 90Y-DOTATOC. J Nucl Med 2002; 43: 610-6. (Pubitemid 34507110)
50. 90Y-DOTATOC results of a phase I study. J Nucl Med 2001; 42: 36P.